Jan 31 (Reuters) – Merck & Co’s (MRK.N) new antiviral pill, once touted as a potential game changer for treating COVID-19, is the last choice among four available options for at-risk patients given its relatively low efficacy and potential safety issues, U.S. doctors, healthcare systems and pharmacies told Reuters. […]

Click here to view original web page at www.reuters.com